{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=95",
    "query": {
      "condition": "Dermatologic Disorders",
      "page": 95
    },
    "page_size": 10
  },
  "pagination": {
    "page": 95,
    "page_size": 10,
    "total_count": 13632,
    "total_pages": 1364,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=96&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=94&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T03:55:12.555Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04684485",
      "title": "To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 1",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 2",
          "type": "DRUG"
        },
        {
          "name": "SCD-044_Dose 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2021-07-30",
      "completion_date": "2025-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Yuma, Arizona • Encino, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684485"
    },
    {
      "nct_id": "NCT05830149",
      "title": "Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Cryoinsufflation",
          "type": "OTHER"
        },
        {
          "name": "Deroofing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-02-20",
      "completion_date": "2018-04-18",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05830149"
    },
    {
      "nct_id": "NCT02143648",
      "title": "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "nalbuphine HCl ER tablets 60 mg BID",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine HCl ER tablets 120mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 373,
      "start_date": "2014-06",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143648"
    },
    {
      "nct_id": "NCT03654755",
      "title": "Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ASN002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asana BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 162,
      "start_date": "2018-09-29",
      "completion_date": "2019-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 31,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654755"
    },
    {
      "nct_id": "NCT01093885",
      "title": "Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 15,
      "start_date": "2010-02",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093885"
    },
    {
      "nct_id": "NCT02171078",
      "title": "Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 34359,
      "start_date": "2014-06",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2022-12-27",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02171078"
    },
    {
      "nct_id": "NCT05099133",
      "title": "A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "LEO 138559",
          "type": "DRUG"
        },
        {
          "name": "LEO 138559 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-11-03",
      "completion_date": "2022-06-28",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099133"
    },
    {
      "nct_id": "NCT01652885",
      "title": "Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "AN2728 Topical Ointment, 2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 23,
      "start_date": "2012-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-24",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 6,
      "location_summary": "Fremont, California • San Diego, California • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652885"
    },
    {
      "nct_id": "NCT00003002",
      "title": "HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "HER-2/neu peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "1996-04",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003002"
    },
    {
      "nct_id": "NCT02370277",
      "title": "Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ductal Breast Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Stage I Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2014-12-16",
      "completion_date": "2018-08-22",
      "has_results": false,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-11-11T03:55:12.555Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370277"
    }
  ]
}